Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

The capacity to induce cross-presentation dictates the success of a TLR7 agonist-conjugate vaccine for eliciting cellular immunity.

Oh JZ, Kedl RM.

J Immunol. 2010 Oct 15;185(8):4602-8. doi: 10.4049/jimmunol.1001892. Epub 2010 Sep 15.

2.

Cross-priming CD8+ T cells by targeting antigens to human dendritic cells through DCIR.

Klechevsky E, Flamar AL, Cao Y, Blanck JP, Liu M, O'Bar A, Agouna-Deciat O, Klucar P, Thompson-Snipes L, Zurawski S, Reiter Y, Palucka AK, Zurawski G, Banchereau J.

Blood. 2010 Sep 9;116(10):1685-97. doi: 10.1182/blood-2010-01-264960. Epub 2010 Jun 7.

3.
4.

Influenza A infection enhances cross-priming of CD8+ T cells to cell-associated antigens in a TLR7- and type I IFN-dependent fashion.

Wei J, Waithman J, Lata R, Mifsud NA, Cebon J, Kay T, Smyth MJ, Sadler AJ, Chen W.

J Immunol. 2010 Nov 15;185(10):6013-22. doi: 10.4049/jimmunol.1002129. Epub 2010 Oct 18.

5.

TLR7 enables cross-presentation by multiple dendritic cell subsets through a type I IFN-dependent pathway.

Oh JZ, Kurche JS, Burchill MA, Kedl RM.

Blood. 2011 Sep 15;118(11):3028-38. doi: 10.1182/blood-2011-04-348839. Epub 2011 Aug 2.

6.

TLR7 triggering with polyuridylic acid promotes cross-presentation in CD8α+ conventional dendritic cells by enhancing antigen preservation and MHC class I antigen permanence on the dendritic cell surface.

Crespo MI, Zacca ER, Núñez NG, Ranocchia RP, Maccioni M, Maletto BA, Pistoresi-Palencia MC, Morón G.

J Immunol. 2013 Feb 1;190(3):948-60. doi: 10.4049/jimmunol.1102725. Epub 2013 Jan 2.

7.

Lymph-borne CD8α+ dendritic cells are uniquely able to cross-prime CD8+ T cells with antigen acquired from intestinal epithelial cells.

Cerovic V, Houston SA, Westlund J, Utriainen L, Davison ES, Scott CL, Bain CC, Joeris T, Agace WW, Kroczek RA, Mowat AM, Yrlid U, Milling SW.

Mucosal Immunol. 2015 Jan;8(1):38-48. doi: 10.1038/mi.2014.40. Epub 2014 May 21.

8.

Protective T cell immunity in mice following protein-TLR7/8 agonist-conjugate immunization requires aggregation, type I IFN, and multiple DC subsets.

Kastenmüller K, Wille-Reece U, Lindsay RW, Trager LR, Darrah PA, Flynn BJ, Becker MR, Udey MC, Clausen BE, Igyarto BZ, Kaplan DH, Kastenmüller W, Germain RN, Seder RA.

J Clin Invest. 2011 May;121(5):1782-96. doi: 10.1172/JCI45416. Epub 2011 Apr 11.

9.

Targeting the gut vascular endothelium induces gut effector CD8 T cell responses via cross-presentation by dendritic cells.

Bourges D, Zhan Y, Brady JL, Braley H, Caminschi I, Prato S, Villadangos JA, Lew AM.

J Immunol. 2007 Nov 1;179(9):5678-85.

10.

CpG promotes cross-presentation of dead cell-associated antigens by pre-CD8α+ dendritic cells [corrected].

de Brito C, Tomkowiak M, Ghittoni R, Caux C, Leverrier Y, Marvel J.

J Immunol. 2011 Feb 1;186(3):1503-11. doi: 10.4049/jimmunol.1001022. Epub 2010 Dec 27. Erratum in: J Immunol. 2011 Jun 15;186(12):7272.

11.

Aging Impairs the Ability of Conventional Dendritic Cells to Cross-Prime CD8+ T Cells upon Stimulation with a TLR7 Ligand.

Zacca ER, Crespo MI, Acland RP, Roselli E, Núñez NG, Maccioni M, Maletto BA, Pistoresi-Palencia MC, Morón G.

PLoS One. 2015 Oct 16;10(10):e0140672. doi: 10.1371/journal.pone.0140672. eCollection 2015.

12.

Antigen persistence is required for dendritic cell licensing and CD8+ T cell cross-priming.

Jusforgues-Saklani H, Uhl M, Blachère N, Lemaître F, Lantz O, Bousso P, Braun D, Moon JJ, Albert ML.

J Immunol. 2008 Sep 1;181(5):3067-76.

13.

Topical rather than intradermal application of the TLR7 ligand imiquimod leads to human dermal dendritic cell maturation and CD8+ T-cell cross-priming.

Fehres CM, Bruijns SC, van Beelen AJ, Kalay H, Ambrosini M, Hooijberg E, Unger WW, de Gruijl TD, van Kooyk Y.

Eur J Immunol. 2014 Aug;44(8):2415-24. doi: 10.1002/eji.201344094. Epub 2014 Jun 24.

14.
15.

Nanoparticle adjuvant sensing by TLR7 enhances CD8+ T cell-mediated protection from Listeria monocytogenes infection.

Lebel MÈ, Daudelin JF, Chartrand K, Tarrab E, Kalinke U, Savard P, Labrecque N, Leclerc D, Lamarre A.

J Immunol. 2014 Feb 1;192(3):1071-8. doi: 10.4049/jimmunol.1302030. Epub 2013 Dec 27.

16.

A marked reduction in priming of cytotoxic CD8+ T cells mediated by stress-induced glucocorticoids involves multiple deficiencies in cross-presentation by dendritic cells.

Hunzeker JT, Elftman MD, Mellinger JC, Princiotta MF, Bonneau RH, Truckenmiller ME, Norbury CC.

J Immunol. 2011 Jan 1;186(1):183-94. doi: 10.4049/jimmunol.1001737. Epub 2010 Nov 22.

17.

Shaping of adaptive immune responses to soluble proteins by TLR agonists: a role for IFN-alpha/beta.

Durand V, Wong SY, Tough DF, Le Bon A.

Immunol Cell Biol. 2004 Dec;82(6):596-602.

18.
19.

Type I IFNs control antigen retention and survival of CD8α(+) dendritic cells after uptake of tumor apoptotic cells leading to cross-priming.

Lorenzi S, Mattei F, Sistigu A, Bracci L, Spadaro F, Sanchez M, Spada M, Belardelli F, Gabriele L, Schiavoni G.

J Immunol. 2011 May 1;186(9):5142-50. doi: 10.4049/jimmunol.1004163. Epub 2011 Mar 25.

20.

Human CD141+ (BDCA-3)+ dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigens.

Jongbloed SL, Kassianos AJ, McDonald KJ, Clark GJ, Ju X, Angel CE, Chen CJ, Dunbar PR, Wadley RB, Jeet V, Vulink AJ, Hart DN, Radford KJ.

J Exp Med. 2010 Jun 7;207(6):1247-60. doi: 10.1084/jem.20092140. Epub 2010 May 17.

Supplemental Content

Support Center